Clinical Trials

NCT IdNCT04872413
TitleInterrogating Biological Signaling Pathway Dysregulations and In Vitro Screening With Personalized Therapies in Relapsed or Refractory Mantle Cell Lymphoma, MCL MATCH Trial
ConditionRecurrent Mantle Cell Lymphoma
StudyTypeInterventional
OrganizationM.D. Anderson Cancer Center
Sponsor/CollaboratorsM.D. Anderson Cancer Center
StatusRecruiting
GenderAll
AgeGroupAdult
Older Adult
Location (with distance)
  • M D Anderson Cancer Center, Houston, 77030 , United States
DescriptionThis clinical trial collects and tests samples using genetic testing to find personalized treatments that may work best for patients with mantle cell lymphoma (MCL) that has come back (relapsed) or does not respond to treatment (refractory). Several types of MCL are difficult to treat due to specific genetic changes (mutations or alterations in the DNA/RNA expression in the cells) that make them not respond to a certain type of drug called a Bruton's tyrosine kinase (BTK) inhibitor. The goal of this clinical research study is to use genetic testing to identify which drugs may be most effective in treating patients with MCL who have this type of genetic mutation.